左卡尼汀联合前列地尔治疗对糖尿病肾病患者肾功能、氧化应激及炎症反应的影响

doi:10.3969/j.issn.1671-7171.2022.05.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1156 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the effects of levocarnitine combined with alprostadil on renal function,oxidative stress and inflammation in patients with diabetic nephropathy (DN). 【Methods】 A total of 98 DN patients treated in Yulin Fifth Medical College from March 2019 to March 2021 were selected and divided into the observation group and the control group according to random number table method,with 49 cases in each group. The control group was treated with alprostadil,and the observation group was treated with L-carnitine on the basis of the control group,for consecutive 4 weeks. Clinical efficacy,renal function indexes [BUN,CYstatin C,24 h urinary protein,β₂ microglobulin,24hUpro,β₂-MG],oxidative stress indexes [MALondialdehyde (MDA),superoxide dismutase (SOD),reactive oxygen species (ROS)] and inflammatory factors [C-reactive protein (CRP), interleukin-1 β (IL-1β), interleukin-6 (IL-6), interleukin-17 (IL-17)] levels and the incidence of adverse reactions were compared between two groups. 【Results】 The total effective rate of observation group was 93.88%, which was significantly higher than that of control group (77.55%), and the difference was statistically significant (P<0.05). After treatment, the levels of BUN, CYS-C, 24hUpro, β₂-MG, MDA, ROS, CRP, IL-1β and IL-6 in the observation group were significantly lower than those in the control group, while SOD was significantly higher than that in the observation group; The differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Levocarnitine combined with alprostadil in the treatment of DN can improve the clinical curative effect, reduce the damage to the kidney, reducing oxidative stress and inflammation index.

Key words： Diabetic Nephropathies/DT Carnitine/TU Alprostadil/TU Kidney Function Tests Oxidative Stress

Received: 29 December 2021

PACS:

R587.24

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JI Dong-lin
	ZHANG Ya-qiong

Cite this article:

JI Dong-lin,ZHANG Ya-qiong. Effects of Levocarnitine Combined with Alprostadil on Renal Function,Oxidative Stress and Inflammatory Response in Diabetic Nephropathy Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 644-647.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.05.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I5/644

[1] GREGG E W, LI Y, WANG J, et al. Changes in diabetes-related complications in the United States, 1990-2010[J].N Engl J Med,2014, 370(16):1514-1523.
[2] 陈碧霞,张利,吴玲玲,等. 糖尿病肾病内皮细胞损伤机制的研究进展[J].解放军医学杂志, 2020, 45(8):94-101.
[3] WEI W, AN X R, JIN S J, et al. Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy[J].Sci Rep,2018, 8(1):8-9.
[4] 杨青娟. 血透联合左卡尼汀法在终末期糖尿病肾病患者治疗中的价值分析[J].临床医学研究与实践, 2017, 2(20):41-42.
[5] 中华医学会肾脏病学分会专家组. 糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3):255-304.
[6] 郑文,潘少康,刘东伟,等.糖尿病肾病治疗进展[J].中华肾脏病杂志, 2020,36(6):476-480.
[7] 李洪清, 安桂凤, 郭德森,等. 以前列地尔为主多因素干预Ⅲ期糖尿病肾病的疗效[J].实用医学杂志, 2019, 35(12):1996-1999.
[8] 夏朝霞, 路伟, 汪代杰,等. 左卡尼汀联合前列地尔治疗糖尿病肾病的临床研究[J].中国临床药理学杂志, 2016,32(13):1172-1174.
[9] 杨莹,范秋灵,李露露,等. miRNA-148b靶向AMPKα1通过氧化应激介导高糖诱导的人肾小管上皮细胞凋亡[J].中华肾脏病杂志, 2019,35(1):43-47.
[10] 张尚维,李明星,赵蕊,等.糖尿病肾病发生的氧化应激机制及抗氧化治疗的研究进展[J].中国药理学与毒理学杂志, 2020, 34(8):76-82.
[11] 梅百强, 唐少梅, 杨希立,等. 前列地尔对慢性肾病患者对比剂肾病的抗氧化应激作用[J].实用放射学杂志, 2018, 34(2):274-277.
[12] 李远彬, 李亚光, 张芯,等. 左卡尼汀对过氧化氢诱导血管内皮细胞氧化应激损伤的影响[J].中国慢性病预防与控制, 2020, 28(4):68-71.
[13] 谭玲玲, 樊均明. IL-17在糖尿病肾病中扮演的角色[J].中国老年学杂志, 2017, 37(19):4951-4952.